Antibiotic resistance in India is no longer a warning for the future. It is already affecting patients in hospitals, families at home, doctors in intensive care units, and pharmacists across the country. A urinary tract infection that once responded quickly to a common medicine can now require stronger drugs. A wound infection after surgery can become difficult to control. A newborn with sepsis, an elderly person with pneumonia, or a cancer patient with a weakened immune system may face fewer treatment choices than doctors had a generation ago.
This is the real meaning of antimicrobial resistance, or AMR. It does not mean the human body becomes resistant to antibiotics. It means bacteria, fungi, viruses or parasites change over time and stop responding to the medicines designed to kill them. In the case of antibiotic resistance, bacteria survive even when antibiotics are used. These surviving bacteria multiply, spread and make infections harder, slower and more expensive to treat.
The World Health Organization describes AMR as one of the top global public health and development threats. WHO estimated that bacterial AMR directly caused 1.27 million deaths worldwide in 2019 and contributed to 4.95 million deaths [1]. In 2025, WHO’s Global Antibiotic Resistance Surveillance Report warned that one in six laboratory-confirmed bacterial infections causing common infections in 2023 were resistant to antibiotic treatment [2]. That number is not just a statistic. It is a sign that modern medicine is losing some of its most important weapons.
For India, the danger is especially urgent. One Health Trust estimates that in India in 2021, there were 1,580,000 deaths from bacterial infections, 987,254 deaths associated with bacterial AMR, and 266,734 deaths attributable to bacterial AMR [3]. These figures make antibiotic resistance in India a national health challenge, an economic challenge and a household-level challenge.
Why antibiotic resistance matters to every Indian family
Antibiotics are among the most important discoveries in medical history. They made it possible to treat pneumonia, tuberculosis, urinary infections, bloodstream infections, wound infections and many other bacterial diseases. They also made modern healthcare safer. Caesarean sections, organ transplants, cancer chemotherapy, dialysis, joint replacements and intensive-care treatment all depend on effective antibiotics.
When antibiotics stop working, the risk of medical care changes. Doctors may need to use more expensive medicines. Patients may need longer hospital stays. Families may spend more on tests, injections and intensive care. Some medicines used for resistant infections can have more side effects. In severe cases, even the strongest available antibiotics may not work.
This is why antibiotic resistance in India should not be seen only as a hospital issue or a scientific issue. It is also a family finance issue, a rural healthcare issue, a food safety issue and a national productivity issue. A resistant infection can push a low-income family into debt. It can turn a routine surgery into a high-risk procedure. It can make a child’s fever, an elderly person’s chest infection or a diabetic patient’s foot wound much harder to manage.
The problem grows silently because resistance is not always visible at the start. A patient may take an antibiotic and feel better for a few days, while resistant bacteria continue spreading. A pharmacy may sell antibiotics without a proper prescription, and the immediate demand may be satisfied, but the long-term risk increases. A hospital may use broad-spectrum antibiotics too often, and the damage may appear later as drug-resistant outbreaks in wards and ICUs.
What is driving antibiotic resistance in India?
The biggest driver of antibiotic resistance is misuse and overuse. WHO states that misuse and overuse of antimicrobials in humans, animals and plants are the main drivers of drug-resistant pathogens [1]. In India, this problem is shaped by a mix of medical, social and economic pressures.
Many patients want quick relief. Some expect antibiotics for fever, cough, sore throat, cold or flu-like illness, even when the cause is viral. Antibiotics do not work against viruses, but they are still often demanded or prescribed “just in case.” Some patients stop medicines early when they feel better. Others reuse leftover tablets or share antibiotics with relatives. In many places, people still buy antibiotics directly from a pharmacy instead of seeing a qualified doctor.
Doctors also face pressure. In busy clinics, a doctor may not have time to explain why an antibiotic is unnecessary. In areas where diagnostic tests are expensive, delayed or unavailable, treatment decisions may be made without laboratory confirmation. In hospitals, doctors treating critically ill patients may start broad-spectrum antibiotics quickly to save lives, but if these medicines are not reviewed and narrowed after test results, resistance pressure increases.
The private medicine market adds another layer. A study of India’s private-sector systemic antibiotic consumption in 2019 found that total consumption was 5,071 million defined daily doses. “Watch” antibiotics, which should be used more cautiously, accounted for 54.9% of consumption, while “Access” antibiotics accounted for only 27.0%. The study also found that unapproved formulations contributed 47.1% of consumed antibiotic doses [5]. This shows that the problem is not only how many antibiotics are used. It is also which antibiotics are used, how they are sold and whether they are clinically necessary.
India’s hospital data shows the scale of the threat
The Indian Council of Medical Research’s AMR Surveillance Network gives one of the clearest pictures of antibiotic resistance in Indian hospitals. The ICMR AMRSN annual report for 2024 studied 99,027 culture-positive isolates from January to December 2024 [4]. The report notes that the data comes from tertiary-care hospitals and should not be directly treated as a picture of community-level AMR across India [4]. Even with that caution, the findings are deeply concerning.
ICMR reported that gram-negative bacteria remained the most commonly isolated pathogens from clinically important samples such as blood, urine, cerebrospinal fluid and respiratory tract samples. Escherichia coli was the most commonly isolated pathogen, followed by Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus [4]. These names may sound technical, but they matter because they are connected with infections Indians see every day: urinary tract infections, pneumonia, bloodstream infections, ventilator-associated infections and hospital-acquired infections.
The most worrying signal is the declining effectiveness of powerful antibiotics. According to the 2024 ICMR report, E. coli susceptibility to imipenem, a carbapenem antibiotic used for serious infections, fell from 81.4% in 2017 to 57.6% in 2024. For K. pneumoniae, imipenem susceptibility fell from 58.5% in 2017 to 31.2% in 2024, while meropenem susceptibility dropped from 48.1% to 35.1% over the same period [4]. In simple language, some of the bacteria that commonly cause serious infections are becoming less responsive to some of the strongest antibiotics used in hospitals.
This does not mean every infection is untreatable. It means doctors have fewer easy choices. It means treatment must become more precise. It means hospitals need stronger infection control, faster diagnostics and stricter antibiotic stewardship. Without these, India risks entering a period where common infections become complicated and expensive.
The pharmacy problem: antibiotics without prescription
Indian law already treats many antibiotics as prescription medicines. Research on over-the-counter antibiotic sales in India explains that Schedule H and Schedule H1 drugs are meant to be sold only on the written prescription of a registered medical practitioner and under the supervision of a registered pharmacist [6]. Yet antibiotics continue to be available without valid prescriptions in many places.
This is not simply a matter of blaming pharmacies. The problem is structural. Patients may live far from a qualified doctor. A consultation may cost more than a medicine strip. Daily-wage workers may not want to lose income by visiting a clinic. Some pharmacies may fear losing customers if they refuse antibiotics. Informal providers may prescribe antibiotics unnecessarily. Online and informal supply chains may make enforcement harder.
However, easy access has a cost. When antibiotics are treated like ordinary fever tablets, resistance spreads faster. A person may take the wrong antibiotic, the wrong dose or the wrong duration. Symptoms may reduce temporarily, but the infection may not be cleared. Resistant bacteria can then spread within families, communities and hospitals.
India needs enforcement, but enforcement alone will not solve the problem. The country also needs accessible primary healthcare, affordable diagnostic tests, pharmacist training, public awareness and a culture where saying “no antibiotic needed” is seen as good medical care, not poor service.
Antibiotic resistance is also a hospital infection-control problem
Hospitals save lives, but they can also become places where resistant bacteria spread. Patients in ICUs, patients with catheters, ventilators, surgical wounds, burns, cancer treatment or long hospital stays are more vulnerable. When antibiotics are used heavily in such settings, bacteria that survive can become dominant.
Hospital-acquired infections are especially dangerous because they often involve bacteria already exposed to multiple antibiotics. If hand hygiene is poor, if equipment cleaning is weak, if isolation practices are not followed, or if antibiotics are used without review, resistant organisms can move from patient to patient.
This is why antibiotic stewardship must become routine in every major Indian hospital. Stewardship means using antibiotics carefully: choosing the right drug, at the right dose, for the right duration, based on the most likely organism and laboratory results whenever possible. It also means stopping antibiotics when they are not needed and switching from broad-spectrum drugs to narrower options when test results allow.
But stewardship cannot work without diagnostics. A doctor cannot choose precisely without knowing what organism is causing the infection and what medicines still work. India needs more microbiology laboratories, faster reporting systems and better links between laboratory data and bedside decisions.
The One Health angle: animals, food and the environment
Antibiotic resistance does not stay inside hospitals. Resistant bacteria and resistance genes can move between humans, animals, food, soil, water and the environment. That is why the AMR fight requires a One Health approach, connecting human health, animal health, agriculture, food safety and environmental protection.
Antibiotic use in food-producing animals has been a major concern globally. When antibiotics are used for growth promotion or routine prevention rather than genuine treatment, bacteria in animals can develop resistance. These bacteria or their resistance genes can spread through meat, milk, eggs, water, soil, farm workers and the food chain.
India has taken some important steps. In 2019, the Union Ministry of Health and Family Welfare prohibited the sale, manufacture and distribution of colistin and its formulations in food-producing animals, poultry, aqua farming and animal feed supplements [7]. Colistin is considered a last-resort antibiotic in human medicine, so protecting it matters for critically ill patients.
Food regulation is also evolving. FSSAI’s 2024 amendment, effective from April 1, 2025, states that certain antibiotics and veterinary drugs are not permitted at any stage of processing for meat and meat products, milk and milk products, poultry and eggs, marine animals and their products [8]. This is a major regulatory signal, but implementation will decide its real impact. India needs routine residue testing, transparent reporting, farm-level compliance and strong coordination between food safety authorities, veterinary services and public health agencies.
Environmental contamination is another concern. Antibiotic residues and resistant bacteria can enter wastewater from hospitals, households, farms and pharmaceutical production. Poor sanitation can then help spread resistant organisms. This is why clean water, safe sanitation and waste management are not separate from AMR control. They are central to it.
Why common infections are becoming harder to treat
For many Indians, antibiotic resistance becomes real only when a common infection does not respond. Urinary tract infections are a good example. E. coli is a major cause of UTIs, and ICMR data shows it is the most commonly isolated pathogen in the surveillance network [4]. When resistance rises, a patient may not improve on the first antibiotic. Doctors may need urine culture tests, injectable medicines or stronger antibiotics.
Pneumonia is another concern. Bacterial pneumonia can become dangerous quickly, especially in children, older adults and people with chronic disease. If first-line antibiotics fail, hospitalization may be needed. In ICUs, organisms such as Klebsiella, Pseudomonas and Acinetobacter can cause severe infections that are difficult to treat.
Bloodstream infections are among the most dangerous. If bacteria enter the blood and cause sepsis, every hour matters. Delayed effective treatment can increase the risk of organ failure and death. Resistant bloodstream infections make that delay more likely because the first antibiotic may not work.
This is why antibiotic resistance in India cannot be solved only by discovering new drugs. New antibiotics are important, but they are not enough. If the same misuse continues, new drugs will also lose power. The first goal must be to reduce unnecessary antibiotic use and prevent infections before they happen.
The economic cost of superbugs in India
Antibiotic resistance increases healthcare costs at every step. A resistant infection often requires more tests, more expensive medicines, longer hospital stays and sometimes ICU care. Families may need to travel to bigger hospitals. Patients may miss work. Caregivers may lose income. For low-income households, the financial shock can be severe.
The economic effect goes beyond individual families. When infections become harder to treat, hospitals become more crowded. Productivity falls. Health insurance costs rise. Surgical and cancer-care risks increase. Public health systems spend more on complications that could have been prevented.
A major global study published in 2024 estimated that in 2021, 4.71 million deaths were associated with bacterial AMR and 1.14 million deaths were attributable to bacterial AMR. It also forecast that by 2050, 1.91 million deaths attributable to AMR and 8.22 million deaths associated with AMR could occur globally, with South Asia among the regions forecast to have high AMR mortality rates [10]. For India, this is a warning that the cost of inaction will not be limited to hospitals. It will be paid by families, employers, farmers, governments and the healthcare system.
India’s response: strong plans, difficult implementation
India has recognized AMR as a national priority. The first National Action Plan on Antimicrobial Resistance was launched in 2017. In November 2025, the Union Health Minister launched National Action Plan on AMR 2.0 for 2025–2029 [9]. The updated plan focuses on awareness, education and training; laboratory capacity; infection control in healthcare facilities; inter-sectoral coordination; and stronger engagement with the private sector [9].
This direction is important because AMR cannot be controlled by one ministry or one profession. Doctors, nurses, microbiologists, pharmacists, veterinarians, farmers, food regulators, pharmaceutical companies, municipalities, schools, media and patients all play a role.
However, India’s challenge is not only planning. It is execution. Policies must translate into working laboratories, trained staff, hospital antibiotic policies, pharmacy inspections, digital prescription systems, state-level action plans, food-animal surveillance, wastewater controls and public education campaigns that people actually understand.
The private sector is especially important because a large share of healthcare and medicine sales in India happens outside government facilities. A national AMR plan that does not deeply engage private clinics, hospitals, diagnostic chains, pharmacies and drug manufacturers will remain incomplete.
What India must do now
India’s AMR response needs discipline, speed and realism. First, antibiotic use must become more evidence-based. Doctors need access to reliable local resistance data and affordable tests. Hospitals should review antibiotic prescriptions, especially broad-spectrum and reserve antibiotics. Every tertiary hospital should have a functioning antimicrobial stewardship committee, but smaller hospitals and clinics also need practical guidance.
Second, pharmacies must stop casual antibiotic sales. This requires enforcement, but also support. Pharmacists should be trained to counsel patients, refuse unsafe requests and refer people to qualified care. Digital prescription tracking for high-risk antibiotics can help, but it must be designed for India’s real-world pharmacy landscape.
Third, infection prevention must be treated as a core AMR strategy. Hand hygiene, clean water, safe sanitation, sterilized equipment, vaccination and hospital cleaning reduce infections and therefore reduce antibiotic use. A 2024 Lancet series analysis estimated that preventive measures such as infection control in healthcare facilities, safe drinking water, sanitation and pediatric vaccines could prevent around 750,000 AMR-associated deaths each year in low- and middle-income countries [11].
Fourth, India needs stronger One Health surveillance. Human hospitals, veterinary services, farms, food testing laboratories and environmental monitoring systems should not work in isolation. Resistant bacteria do not respect departmental boundaries.
Fifth, the public message must be simple and repeated often: antibiotics are not fever medicines. They are not for most colds or viral coughs. They should not be shared, saved, reused or stopped early without medical advice. Every unnecessary antibiotic dose today can make tomorrow’s infection harder to treat.
What readers can do
Ordinary citizens cannot solve AMR alone, but they can slow it. The most important step is to avoid self-medication. Do not take antibiotics without medical advice. Do not pressure a doctor for antibiotics for a viral illness. Do not buy antibiotics because a similar medicine helped last year. Do not share leftover tablets with a family member.
When a doctor prescribes an antibiotic, ask what infection it is meant to treat and how long it should be taken. If a test is recommended, do not ignore it only because symptoms seem familiar. If symptoms do not improve, do not keep changing antibiotics on your own. Return to a qualified healthcare provider.
Families can also prevent infections through vaccination, hand hygiene, safe food handling, clean drinking water and timely care for wounds, diabetes-related foot problems and respiratory infections. Prevention is not glamorous, but it is powerful. Every infection prevented is one less chance for antibiotic misuse and resistance.
The bottom line
Antibiotic resistance in India is one of the biggest health challenges of this generation. It threatens common infection treatment, hospital safety, surgery, cancer care, newborn survival and family finances. The danger is serious, but it is not hopeless.
India has scientific expertise, surveillance networks, national plans and regulatory tools. What it needs now is consistent implementation. Antibiotics must remain available to patients who truly need them, but they must be protected from careless use. Hospitals must improve infection control. Pharmacies must follow prescription rules. Food-animal antibiotic use must be monitored. Patients must stop treating antibiotics as quick-fix medicines.
The future of antibiotics will be decided by millions of small decisions: a doctor choosing carefully, a pharmacist refusing unsafe sales, a hospital cleaning a device properly, a farmer avoiding unnecessary antibiotic use, a parent not demanding antibiotics for a viral fever, and a government enforcing rules fairly.
Antibiotics changed the history of medicine. If India acts now, it can help protect them for the next generation. If it delays, the country may face a future where common infections become costly, dangerous and sometimes untreatable. The superbug crisis is already here. The question is whether India will control it before it controls us.
References
[1] World Health Organization, “Antimicrobial resistance.” Brief: Explains AMR, global mortality estimates and the role of misuse and overuse in humans, animals and plants.
https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance (World Health Organization)
[2] World Health Organization, “WHO warns of widespread resistance to common antibiotics worldwide,” 2025. Brief: Summarizes WHO GLASS 2025 findings, including one in six resistant laboratory-confirmed bacterial infections globally in 2023.
https://www.who.int/news/item/13-10-2025-who-warns-of-widespread-resistance-to-common-antibiotics-worldwide (World Health Organization)
[3] One Health Trust, “The Impact of Antimicrobial Resistance in India.” Brief: Provides India-specific estimates for deaths from bacterial infections, AMR-associated deaths and AMR-attributable deaths in 2021.
https://onehealthtrust.org/publications/infographics/the-impact-of-antimicrobial-resistance-in-india/ (One Health Trust)
[4] Indian Council of Medical Research, “ICMR Antimicrobial Resistance Research and Surveillance Network Annual Report 2024.” Brief: Provides India hospital surveillance data on culture-positive isolates, common pathogens and antibiotic susceptibility trends.
https://www.icmr.gov.in/icmrobject/uploads/Report/1763981012_icmramrsnannualreport2024.pdf
[5] Koya SF et al., “Consumption of systemic antibiotics in India in 2019,” PubMed / The Lancet Regional Health – Southeast Asia. Brief: Analyzes private-sector antibiotic consumption in India using WHO AWaRe categories and defined daily doses.
https://pubmed.ncbi.nlm.nih.gov/37383993/ (PubMed)
[6] Porter G, Kotwani A, Bhullar L, Joshi J., “Over-the-counter sales of antibiotics for human use in India: The challenges and opportunities for regulation,” 2021. Brief: Explains India’s Schedule H and H1 prescription rules and the continuing OTC antibiotic sales challenge.
https://journals.sagepub.com/doi/10.1177/09685332211020786 (Sage Journals)
[7] Centre for Science and Environment, “CSE welcomes government’s ban on colistin,” 2019. Brief: Covers India’s prohibition on colistin sale, manufacture and distribution for food-producing animals, poultry, aqua farming and animal feed supplements.
https://www.cseindia.org/cse-welcomes-government-s-ban-on-colistin-9605 (cseindia.org)
[8] Food Safety and Standards Authority of India, “Food Safety and Standards First Amendment Regulations, 2024.” Brief: Official gazette notification stating the 2024 amendment and its April 1, 2025 effective date for updated contaminant, toxin and residue rules.
https://fssai.gov.in/upload/notifications/2024/10/67178d79690b3antibiotic%20gazette.pdf
[9] Press Information Bureau, Government of India, “Union Health Minister Shri J P Nadda Launches National Action Plan on Antimicrobial Resistance 2.0,” 2025. Brief: Official release on India’s NAP-AMR 2.0 for 2025–2029 and its implementation priorities.
https://www.pib.gov.in/PressReleasePage.aspx?PRID=2191165 (Press Information Bureau)
[10] Naghavi M et al., “Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050,” PubMed / The Lancet, 2024. Brief: Provides global AMR burden estimates and forecasts to 2050, including high-risk regions.
https://pubmed.ncbi.nlm.nih.gov/39299261/ (PubMed)
[11] UC Berkeley Public Health, “New Lancet series: 750,000 deaths linked to antimicrobial resistance could be prevented every year,” 2024. Brief: Summarizes Lancet series findings on infection prevention, WASH and vaccination as AMR prevention tools.
https://publichealth.berkeley.edu/articles/spotlight/research/deaths-linked-to-antimicrobial-resistance (publichealth.berkeley.edu)
